Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at World Conference on Lung Cancer

Mechanisms of acquired resistance to first-line amivantamab plus lazertinib vs osimertinib: updated analysis from MARIPOSA

CARVYKTI_US-SR-10459

rybrevant dossier update - bottom

Lazcluze Dossier Update - bottom

Talvey Digital Dossier banner

CARVYKTI_US-SR-10545

Imaavy Dossier banner

Test-EL

Externally Sponsored Scientific Research

Submit your medical inquiry

Contact J&J Medical Connect for your medical inquiries


This page was last modified on

Additional contact #{index}

janssenscience

Congress Materials

Payer

Dark Blue

oncology

mechanisms-of-acquired-resistance-video

Whitelist Modal

Mechanisms of acquired resistance to first-line amivantamab plus lazertinib vs osimertinib: updated analysis from MARIPOSA

Connect with us

Connect with us

Live video

Waiting for agent...

Ready to join